Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.

NMD Pharma, a Denmark-based biotechnology spinout from Aarhus University, raised €38m ($47m) in a series A round on Friday co-led by Roche Venture Fund, the corporate venturing arm of healthcare company Roche. Inkef Capital, a Netherlands-based VC firm, co-led the round, which also featured Novo Seeds and Lundbeckfonden Emerge, respective early-stage investment units for pharmaceutical…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.